Abstract: The invention provides, FXR agonists for the treatment of a condition mediated by Farnesoid X receptor (FXR), in particular liver disease or intestinal disease, in a subject in need thereof, to reduce drug-induced adverse side effects inpatients suffering from such diseases or conditions.

Abstract: The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 ?g to about 250 ?g, to a subject in need thereof.

Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g.. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific doses of tropifexor, in particular for treating or preventing liver diseases.

Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.

Abstract: The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.

Abstract: This application discloses a novel method of identifying patients amongst treatment naïve patients suffering from HCV infection that are amenable to treatment with a protease inhibitor. The application also discloses a method of treating treatment naïve, nonresponder and relapsed patients suffering from an HCV infection.

Abstract: Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating activity of HCV protease, or inhibiting cathepsin activity in a subject using the same, in which the mean volume of distribution/bioavailability (Vd/F) of the compound as measured in the plasma of the subject is greater than about 1000 L.

Abstract: Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

Abstract: Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant therapy comprising s-adenosyl methionine, preferably S-adenosyl L-methionine, for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.